Moleculin Biotech Inc. reported a preliminary, blinded composite complete remission (CRc) rate of 40% (30% complete remission and 10% complete remission with partial hematological recovery) in the first 30 treated patients in its pivotal Phase 2B/3 MIRACLE trial evaluating annamycin (naxtarubicin) plus cytarabine versus cytarabine plus placebo in adults with relapsed or refractory acute myeloid leukemia after one prior induction therapy. As of Feb. 10, 2026, 35 subjects had been treated, with the company targeting treatment of the first 45 subjects in Q1 2026; unblinding of efficacy and safety data for those 45 subjects is expected in late Q2 2026 following data entry, audit, and data lock. A second unblinding for the full 90 subjects in Part A is expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656439-en) on February 18, 2026, and is solely responsible for the information contained therein.